The Manufacturers Life Insurance Company boosted its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,467 shares of the biotechnology company’s stock after buying an additional 1,604 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.07% of Sarepta Therapeutics worth $2,585,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in SRPT. Jennison Associates LLC boosted its position in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after acquiring an additional 6,357 shares during the last quarter. Eagle Asset Management Inc. raised its stake in Sarepta Therapeutics by 26.0% during the third quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock valued at $49,858,000 after purchasing an additional 207,810 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its stake in Sarepta Therapeutics by 63.4% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock valued at $48,564,000 after purchasing an additional 338,737 shares in the last quarter. Elk Creek Partners LLC raised its stake in Sarepta Therapeutics by 21.1% during the third quarter. Elk Creek Partners LLC now owns 716,516 shares of the biotechnology company’s stock valued at $32,501,000 after purchasing an additional 124,647 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in Sarepta Therapeutics during the third quarter valued at $26,011,000. Institutional investors own 84.98% of the company’s stock.
Several brokerages have recently weighed in on SRPT. JPMorgan Chase increased their target price on shares of Sarepta Therapeutics from $75.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, March 14th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $91.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, March 14th. BidaskClub raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. SunTrust Banks raised their price target on shares of Sarepta Therapeutics to $95.00 and gave the stock a “buy” rating in a research note on Friday, March 16th. Finally, Morgan Stanley downgraded shares of Sarepta Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $64.00 to $87.00 in a research note on Wednesday, March 21st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $78.87.
SRPT opened at $71.74 on Friday. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. The company has a market cap of $4,805.80, a price-to-earnings ratio of -43.74 and a beta of 1.29. Sarepta Therapeutics Inc has a 12-month low of $28.14 and a 12-month high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The firm had revenue of $57.30 million for the quarter, compared to analysts’ expectations of $57.33 million. During the same period last year, the firm earned ($0.71) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 961.1% compared to the same quarter last year. analysts expect that Sarepta Therapeutics Inc will post -1.18 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/the-manufacturers-life-insurance-company-acquires-1604-shares-of-sarepta-therapeutics-inc-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.